Too few cardiovascular clinical trials adjust for multiplicity to avoid possible statistical flaws, a recent study finds. Two study authors outline steps to fix this and explain why trust in clinical research may be at stake.
We were recruiting patients for 75+ cardiovascular clinical trials when COVID-19 struck. Here’s how we’ve worked to keep as many of them on track as possible.
Pregnant women have largely been left out of clinical trials related to COVID-19, increasing the risk to them, as well as their children and families. In this article, Ruth Farrell, MD, MA, explains the reasoning behind a new, city-wide, multi-institution study investigating the impact of COVID-19 on pregnant women and their babies.
Cleveland Clinic is involved in a range of multicenter and single-center trials of therapies and preventive efforts to combat the virus. Here’s a sampling, along with details on some broader COVID-19 research initiatives.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
A review of recent major cardiovascular medicine studies reveals that only 1 in 10 first authors, senior authors and trial leadership committee members are women.
We profile four ongoing Cleveland Clinic-led clinical studies that are evaluating mechanistically diverse strategies to extend survival in patients with this formidable malignancy.
A new, multicenter trial has begun enrolling patients to evaluate the role of specific behavioral interventions to prevent the development, progression and recurrence of urinary stone disease in adults and children. This first-of-its kind, randomized clinical trial will extend over a two-year period.
For a full listing of all open and accruing studies, please visit the Head & Neck cancer section of Cleveland Clinic’s Cancer Clinical Trials Database.
A review of deintensification trials in the treatment of HPV-related oropharyngeal cancer finds no role for deviating from standards of adjuvant care outside clinical trials, though surgical deintensification via transoral robotic surgery may help reduce treatment-related morbidity.
NCI selected Brian Hobbs, PhD, to lead a subcommittee of NCI’s Clinical Trials Design Task Force with the goal of providing national, consensus recommendations for first-in-human cancer drug trials. Dr. Hobbs is an expert in statistical methods for clinical trial design.